We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+7.39%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$7.43B
AUM Growth
+$757M
(+11%)
Cap. Flow
+$285M
Cap. Flow
% of AUM
3.83%
Top 10 Holdings %
Top 10 Hldgs %
21.69%
Holding
281
New
28
Increased
104
Reduced
67
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$124M |
| 2 |
Medtronic
MDT
|
+$67.1M |
| 3 |
Becton Dickinson
BDX
|
+$51.8M |
| 4 |
RTX Corp
RTX
|
+$51.1M |
| 5 |
Humana
HUM
|
+$44.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$82.1M |
| 2 |
Baxter International
BAX
|
+$49.3M |
| 3 |
Incyte
INCY
|
+$42.4M |
| 4 |
Stryker
SYK
|
+$34.6M |
| 5 |
Pediatrix Medical
MD
|
+$33.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.39% |
| 2 | Healthcare | 23.32% |
| 3 | Technology | 19.99% |
| 4 | Communication Services | 10.16% |
| 5 | Industrials | 7.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
eBay
EBAY
$48.6B
| $9.09M | 0.12% |
260,493
+19,100
| +8% | +$654K |
|
152
Boston Scientific
BSX
$65.8B
| $8.43M | 0.11% |
304,266
-1,260,734
| -81% | -$33.5M |
|
153
Blackstone
BX
$104B
| $8.34M | 0.11% |
249,993
-534
| -0.2% | -$16.8K |
|
154
SLR Investment Corp
SLRC
$706M
| $8.26M | 0.11% |
377,500
-15,000
| -4% | -$331K |
|
|
155
Incyte
INCY
$23.5B
| $8.18M | 0.11% |
65,000
-333,009
| -84% | -$42.4M |
|
156
Biogen
BIIB
$29.9B
| $8.14M | 0.11% |
30,000
+7,000
| +30% | +$1.85M |
|
157
Ares Capital
ARCC
$13.5B
| $7.99M | 0.11% |
487,500
-22,500
| -4% | -$379K |
|
158
Mastercard
MA
$477B
| $7.7M | 0.1% |
63,373
+4,208
| +7% | +$499K |
|
159
Intel
INTC
$466B
| $7.68M | 0.1% |
227,660
-580,034
| -72% | -$20.8M |
|
|
ICPT
160
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $7.26M | 0.1% |
60,000
+25,000
| +71% | +$2.9M |
|
161
Aurinia Pharmaceuticals
AUPH
$1.97B
| $7.25M | 0.1% |
+1,183,272
| New | +$7.97M |
|
162
Take-Two Interactive
TTWO
$43B
| $7.17M | 0.1% |
97,743
+14,871
| +18% | +$1.02M |
|
|
TSRO
163
DELISTED
TESARO, Inc.
TSRO
| $6.99M | 0.09% |
50,000
+25,000
| +100% | +$3.62M |
|
164
KLA
KLAC
$275B
| $6.91M | 0.09% |
754,780
-443,150
| -37% | -$4.42M |
|
165
KeyCorp
KEY
$24.3B
| $6.83M | 0.09% |
364,531
+96,642
| +36% | +$1.75M |
|
166
US Bancorp
USB
$99.6B
| $6.64M | 0.09% |
127,827
-2,886
| -2% | -$149K |
|
167
PennantPark Floating Rate Capital
PFLT
$681M
| $6.49M | 0.09% |
460,000
-27,500
| -6% | -$384K |
|
168
Vertex Pharmaceuticals
VRTX
$121B
| $6.44M | 0.09% |
50,000
+35,000
| +233% | +$4.21M |
|
169
Protolabs
PRLB
$1.86B
| $6.13M | 0.08% |
91,169
+25,746
| +39% | +$1.56M |
|
170
Littelfuse
LFUS
$10.2B
| $6.1M | 0.08% |
+36,965
| New | +$5.94M |
|
|
PPBI
171
DELISTED
Pacific Premier Bancorp
PPBI
| $6.07M | 0.08% |
164,590
+7,015
| +4% | +$253K |
|
172
Gilead Sciences
GILD
$161B
| $6.02M | 0.08% |
85,000
-5,000
| -6% | -$333K |
|
173
Rapid7
RPD
$634M
| $5.94M | 0.08% |
353,315
+20,249
| +6% | +$349K |
|
|
SIVB
174
DELISTED
SVB Financial Group
SIVB
| $5.93M | 0.08% |
33,724
-566
| -2% | -$101K |
|
|
PPLI
175
People Inc
PPLI
$3.1B
| $5.53M | 0.07% |
299,455
| – | – |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2017 Portfolio in Review
As of Q2 2017, Polar Capital held 281 positions worth $7.43B, up 11% from $6.67B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Polar Capital deployed $285M of net new capital in Q2 2017, opening 28 new positions and adding to 104 existing holdings. Its largest new stake was RTX Corp: 681,946 shares worth $52.4M.
By sector, the portfolio is most concentrated in Financials at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Merck, an estimated $82.1M trimmed.
- Polar Capital's largest Q2 2017 buy was RTX Corp: 681,946 shares worth $52.4M.
- Polar Capital added most to Johnson & Johnson in Q2 2017, an estimated $124M increase.
- Polar Capital's biggest Q2 2017 reduction was Merck, cutting an estimated $82.1M.
- Polar Capital fully exited Baxter International in Q2 2017, selling an estimated $49.3M.
- Polar Capital's ten largest holdings make up 22% of its $7.43B portfolio in Q2 2017.
- Polar Capital opened 28 new positions and closed 44 in Q2 2017.
- Polar Capital's portfolio value rose 11% quarter-over-quarter to $7.43B.
Based on Polar Capital's 13F filing for Q2 2017, filed 14 Aug 2017.